In 2023, the first phase 2 clinical trial demonstrating a clinical benefit of PD-1 agonism was published, describing the use of peresolimab, a humanized IgG1 monoclonal antibody that stimulates PD-1, in the treatment of moderate-to-severe rheumatoid arthritis. Here, PDCD1 is linked to rheumatoid arthritis.